Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donafenib + sintilimab
- Development stage
- Phase 2
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Donafenib + sintilimab is a combination therapy consisting of donafenib, an oral small molecule multikinase inhibitor targeting multiple kinases involved in tumor angiogenesis and proliferation (notably VEGFR, PDGFR, RAF kinases), and sintilimab, a monoclonal antibody immune checkpoint inhibitor targeting programmed death 1 (PD-1) receptor. This combination is being investigated primarily for the treatment of hepatocellular carcinoma (HCC), including advanced/unresectable HCC and as neoadjuvant or adjuvant therapy in resectable cases. The rationale for combining these agents is to leverage the antiangiogenic effects of donafenib with the immunomodulatory activity of sintilimab to enhance antitumor efficacy. Clinical studies have shown promising results in terms of progression-free survival and overall response rates with an acceptable safety profile[6][9].
- Brand names
- Zepulid
- Other names
- donafenib plus sintilimabDon-Sin
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)FLT3 (Fms related receptor tyrosine kinase 3)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))
Beyond the preview
Go deeper on donafenib + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donafenib + sintilimab.